Program
giredestrant
Also written as “Giredestrant”, “GDC-9545” and “[14C]-GDC-9545”.
Its studies are mostly in Breast Neoplasms · Neoplasm Metastasis · Endometrial Neoplasms · Ovarian Neoplasms, led by Hoffmann-La Roche.
Furthest: phase 3, since Sep 8, 202017 company-led studies, 12 open or runningNext primary completion: Jul 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Roche | 1712 open or running | phase 3since Sep 8, 2020 | Nov 1, 2017 | Jul 31, 2027phase 1 · NCT03332797 |
- Named in Hoffmann-La Roche’s own pipeline as
RG6171 giredestrant
, phase 4, as of Oct 22, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Nov 1, 2017.
- Sep 8, 2020Phase 3 study in Breast NeoplasmsNCT04546009 · 992 enrolled · United States, Argentina, Australia and more
- Sep 30, 2020Phase 2 study in Breast NeoplasmsNCT04576455 · 303 enrolled · United States, Argentina, Australia and more
- Dec 17, 2020Phase 1 study in Healthy VolunteersNCT04680273 · 16 enrolled · United Kingdom
- Mar 15, 2021Phase 2 study in Neoplasm MetastasisNCT04802759 · 316 planned · United States, Australia, Israel and more
- Jun 9, 2021Phase 2 study in Ovarian NeoplasmsNCT04931342 · 176 enrolled · United States, Australia, Canada and more
- Jul 5, 2021Phase 3 study in Breast NeoplasmsNCT04961996 · 4,170 enrolled · United States, Argentina, Australia and more
- Mar 23, 20222 phase 3 studies in Breast NeoplasmsNCT05306340, NCT05296798
- Nov 21, 2022Phase 2 study in Endometrial NeoplasmsNCT05634499 · 33 enrolled · United States, Canada, Italy and more
- Sep 26, 2023Phase 3 study in Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06065748 · 1,050 enrolled · United States, Argentina, Australia and more
- Jun 26, 2025Phase 2 study in Breast NeoplasmsNCT07054190 · 120 planned · United States, Argentina, Brazil and more
- Apr 15, 2026Phase 3 study in Breast NeoplasmsNCT07541079 · 300 planned · United States
- Sep 15, 2026Phase 3 study in Breast NeoplasmsNCT07827573 · 1,500 planned · United States, Canada
- Sep 29, 2026Primary completion moved from 2027-10-31 to 2027-12-31Date moved laterphase 3 · +2 months · NCT05296798
- Oct 2, 2026Primary completion moved from 2027-12-31 to 2028-06-15Date moved laterphase 3 · +5 months · NCT05296798
Ahead
- Jul 31, 2027Primary completion: phase 2 study in Breast NeoplasmsNCT07054190
- Jul 31, 2027Primary completion: phase 1 study in Breast NeoplasmsNCT03332797
- Feb 28, 2028Primary completion: phase 2 study in Ovarian NeoplasmsNCT04931342
- Apr 20, 2028Primary completion: phase 3 study in Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerNCT06065748
TargetBeta
“An orally available selective estrogen receptor degrader/downregulator (SERD), with potential antineoplastic activity. Upon oral administration, giredestrant specifically targets and binds to the estrogen receptor (ER) and induces a conformational change that promotes ER degradation. This prevent…”NCIt, read by Claude
“An orally available selective estrogen receptor degrader/downregulator (SERD), ”NCIt, by rule
“Estrogen receptor alpha degrader”ChEMBL 37, by rule
Other programs on ESR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Ethinyl Estradiolrule | Johnson & Johnson | phase 4 | 70 |
| Estradiolrule | Novo Nordisk | phase 4 | 69 |
| Fulvestrantrule | AstraZeneca | phase 4 | 30 |
| Tamoxifenrule | AstraZeneca | phase 4 | 21 |
| Clomiphenerule | Hamad Medical | phase 4 | 3 |
| vepdegestrantrule | Pfizer | phase 3 | 20 |
| camizestrantrule | AstraZeneca | phase 3 | 18 |
| HRS-8080 | Jiangsu HengRui Medicine | phase 3 | 13 |
| elacestrantrule | Menarini Group | phase 3 | 12 |
| Imlunestrantrule | Eli Lilly | phase 3 | 12 |
| taragarestrantrule | InventisBio | phase 3 | 5 |
| SIM0270rule | Simcere Pharmaceutical Group | phase 3 | 5 |
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07827573Breast Neoplasms · United States, Canada | 3 | Recruiting | Nov 30, 2028 | 1,500 |
| NCT07541079Breast Neoplasms · United States | 3 | Recruiting | Jun 30, 2032 | 300 |
| NCT07054190Breast Neoplasms · United States, Argentina, Brazil and more | 2 | Recruiting | Jul 31, 2027 | 120 |
| NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 20, 2028 | 1,050 |
| NCT05634499Endometrial Neoplasms · United States, Canada, Italy and more | 2 | Completed | Aug 25, 2026 | 33 |
| NCT05306340Breast Neoplasms · United States, Argentina, Germany and more | 3 | Active, not recruiting | Jul 16, 2025 | 373 |
| NCT05296798Breast Neoplasms · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Jun 15, 2028 | 922 |
| NCT04961996Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Aug 8, 2025 | 4,170 |
| NCT04931342Ovarian Neoplasms · United States, Australia, Canada and more | 2 | Active, not recruiting | Feb 28, 2028 | 176 |
| NCT04802759Neoplasm Metastasis · United States, Australia, Israel and more | 2 | Recruiting | May 30, 2029 | 316 |
| NCT04680273Healthy Volunteers · United Kingdom | 1 | Completed | Apr 12, 2021 | 16 |
| NCT04576455Breast Neoplasms · United States, Argentina, Australia and more | 2 | Active, not recruiting | Feb 18, 2022 | 303 |
| NCT04546009Breast Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 30, 2026 | 992 |
| NCT04436744Breast Neoplasms · United States, Australia, Brazil and more | 2 | Completed | Jul 6, 2021 | 221 |
| NCT04274075Healthy Volunteers · United States | 1 | Completed | Apr 16, 2020 | 18 |
| NCT03916744Breast Neoplasms · United States, Australia, Belgium and more | 1 | Completed | May 25, 2021 | 75 |
| NCT03332797Breast Neoplasms · United States, Australia, South Korea and more | 1 | Active, not recruiting | Jul 31, 2027 | 181 |
How it is read
Names in the registry
- “Giredestrant”, 14 entries
- “GDC-9545”, 1 entry
- “[14C]-GDC-9545”, 1 entry
- “GDC-9545 Solution for Infusion”, 1 entry
- “GDC-9545/F12 Capsule”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 12 studies
- Neoplasm Metastasis, 1 study
- Endometrial Neoplasms, 1 study
- Ovarian Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.